Von Willebrand Disease Treatment Market Size (2024 - 2029)

The Von Willebrand disease treatment market is anticipated to experience significant growth over the forecast period, driven by factors such as increased patient assistance programs and rising healthcare expenditure. The COVID-19 pandemic has notably influenced the market, creating opportunities for treatment availability due to the correlation between elevated von Willebrand factor levels and worse COVID-19 outcomes. The growing incidence and prevalence of VWD globally are prompting the development of new drugs and therapies, further contributing to market expansion. Despite these positive trends, challenges such as a lack of awareness and high treatment costs may impede market growth.

Home Market Analysis Healthcare Research Pharmaceuticals Research Disease Specific Drugs Research Genetic Disorder Drugs Research Von Willebrand Disease Treatment Market Market Size

Market Size of Von Willebrand Disease Treatment Industry

Von Willebrand Disease Treatment Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 6.50 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Von Willebrand Disease Treatment Market Major Players

*Disclaimer: Major Players sorted in no particular order

Von Willebrand Disease Treatment Market Analysis

The Von Willebrand disease (VWD) treatment market is expected to register a CAGR of 6.5% during the forecast period.

The COVID-19 pandemic significantly impacted the studied market. As per a research article published in the ALM journal in September 2021, patients with COVID-19 significantly elevated levels of the von Willebrand factor (vWF) antigen, contributing to an increased risk of thrombosis that was seen in COVID-19-associated coagulopathy (CAC). As per the same source, the high levels of vWF antigen and activity have been clinically correlated with worse outcomes. Thus, it created opportunities for the availability of VWD treatment and impacted the market considerably. Therefore, COVID-19 impacted the studied market significantly and is expected to continue its strong growth over the forecast period.

Factors such as increased patient assistance programs and growing healthcare expenditure are expected to fuel the market's growth during the forecast period.

In July 2021, the PAN Foundation opened a new patient assistance program for people with VWD. The patients who qualify for this program receive USD 10,200 per year in financial assistance to pay for the deductibles, co-pays, and coinsurance costs associated with the treatment for the disease. Another initiative is the Octapharma Co-Pay Assistance Program. This program is available through Factor My Way and provides eligible patients with significant savings on some of the costs associated with their treatment. Such programs propel the demand for treating Von Willebrand's disease, contributing to the market's growth.

Furthermore, the incidence and prevalence of VWD disease are increasing globally and creating new opportunities for developing new drugs, therapies, and treatments available in the market. For instance, according to the Clinical guidelines for VWD published in January 2021 by the World Federation of Hemophilia (WFH), the annual prevalence of VWD ranges from 1 in 100 to 1 in 10,000 globally and requires medical attention for bleeding.

In addition, as per a research study published in the Journal of Blood Medicine in March 2023, approximately 0.6% - 1.3% of the general population was affected by VWD, and the prevalence of symptomatic VWD was approximately 10 per 100,000 during the study period of the research. This disease burden is attracting the focus of government bodies and market players toward the investments and development of innovative drugs, contributing to the studied market growth. Thus, the market is expected to grow over the forecast period due to the abovementioned factors.

However, the need for more awareness and the high cost of the treatment are the factors hindering the market growth.

Von Willebrand Disease Treatment Industry Segmentation

As per the scope of the report, Von Willebrand disease (VWD) is a genetic disorder that delays the process of blood clotting. It is generally caused by a missing or defective Von Willebrand factor (VWF), a clotting protein. The Von Willebrand Disease Treatment Market is Segmented by Disease Type (Type 1, Type 2, Type 3, and Acquired VWD), Treatment Type (Desmopressin, Replacement Therapies, Clot-Stabilizing, and Other Treatment Types), Route of Administration (Oral, Injection, and Other Routes of Administration), and Geography (North America, Europe, Asia Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (USD) for the above segments.

By Disease Type
Type 1
Type 2
Type 3
Acquired VWD
By Treatment Type
Desmopressin
Replacement Therapies
Clot-stabilizing Medications
Other Treatment Types
By Route of Administration
Oral
Injection
Other Routes of Administration
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Von Willebrand Disease Treatment Market Size Summary

The Von Willebrand disease (VWD) treatment market is poised for significant growth, driven by factors such as increased healthcare expenditure and patient assistance programs. The COVID-19 pandemic has notably impacted the market, as elevated levels of the von Willebrand factor antigen in COVID-19 patients have highlighted the need for effective VWD treatments. This has created opportunities for market expansion. The rising incidence and prevalence of VWD globally are prompting the development of new drugs and therapies, further fueling market growth. Despite challenges like high treatment costs and limited awareness, the market is expected to grow steadily, with replacement therapy emerging as a key segment due to its effective results and ongoing research.

North America holds a substantial share of the VWD treatment market, with the United States leading due to the high prevalence of the disease and the availability of innovative treatments. The region benefits from a focus on cost-effective drugs and strategic initiatives to raise awareness. The competitive landscape features major players like Bayer AG, CSL Behring, and Takeda, who are actively seeking product approvals to enhance their market presence. Recent approvals, such as the USFDA's endorsement of novel therapies, are expected to drive further growth. The market's expansion is supported by ongoing research and development, as well as initiatives to address unmet needs in VWD treatment.

Explore More

Von Willebrand Disease Treatment Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increase in Patient Assistance Programs

      2. 1.2.2 Growing Healthcare Expenditure

    3. 1.3 Market Restraints

      1. 1.3.1 Lack of Awareness

      2. 1.3.2 High Cost of Treatment

    4. 1.4 Porter Five Forces

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Disease Type

      1. 2.1.1 Type 1

      2. 2.1.2 Type 2

      3. 2.1.3 Type 3

      4. 2.1.4 Acquired VWD

    2. 2.2 By Treatment Type

      1. 2.2.1 Desmopressin

      2. 2.2.2 Replacement Therapies

      3. 2.2.3 Clot-stabilizing Medications

      4. 2.2.4 Other Treatment Types

    3. 2.3 By Route of Administration

      1. 2.3.1 Oral

      2. 2.3.2 Injection

      3. 2.3.3 Other Routes of Administration

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Von Willebrand Disease Treatment Market Size FAQs

The Global Von Willebrand Disease Treatment Market is projected to register a CAGR of 6.5% during the forecast period (2024-2029)

CSL Behring, Grifols, S.A., Takeda Pharmaceutical Company Ltd, Octapharma AG and Bio Products Laboratory Ltd. are the major companies operating in the Global Von Willebrand Disease Treatment Market.

Von Willebrand Disease Treatment Market Report Snapshots

Von Willebrand Disease Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)